Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Latorre, F. Novelli, B. Vagaggini, F. Braido, Alberto Papi, Alessandro Sanduzzi, P. Santus, Nicola Scichilone, P. Paggiaro (2015)
Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.Pulmonary pharmacology & therapeutics, 30
F. Tonin, Inajara Rotta, Antonio Mendes, R. Pontarolo (2017)
Network meta-analysis: a technique to gather evidence from direct and indirect comparisonsPharmacy Practice, 15
A. Ismaila, K. Haeussler, A. Czira, J. Youn, M. Malmenäs, N. Risebrough, J. Agarwal, M. Nassim, Raj Sharma, C. Compton, C. Vogelmeier, M. Han, D. Halpin (2022)
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-AnalysisAdvances in Therapy, 39
B. Navarrete, I. Boucot, I. Naya, L. Tombs, D. Lipson, C. Compton, A. Sousa, G. Feldman (2018)
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc AnalysisPulmonary Therapy, 4
D. Hoaglin, N. Hawkins, J. Jansen, D. Scott, R. Itzler, J. Cappelleri, C. Boersma, D. Thompson, K. Larholt, M. Diaz, Annabel Barrett (2011)
Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 14 4
A. Bourdin, N. Molinari, G. Ferguson, Barinder Singh, M. Siddiqui, U. Holmgren, M. Ouwens, M. Jenkins, E. Nigris (2021)
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisAdvances in Therapy, 38
A. Ismaila, K. Haeussler, A. Czira, V. Tongbram, M. Malmenäs, J. Agarwal, M. Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, M. Duarte, C. Compton, C. Vogelmeier, D. Halpin (2022)
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-AnalysisAdvances in Therapy, 39
F. Maltais, G. Ferguson, G. Feldman, G. Deslée, A. Bourdin, H. Fjällbrant, Agnieszka Siwek-Posłuszna, M. Jenkins, U. Martin (2019)
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPDAdvances in Therapy
(EMC. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension - summary of product characteristics. 2022. https://www.medicines.org.uk/emc/product/12028/smpc. Accessed 12 Jan 2023.)
EMC. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension - summary of product characteristics. 2022. https://www.medicines.org.uk/emc/product/12028/smpc. Accessed 12 Jan 2023.EMC. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension - summary of product characteristics. 2022. https://www.medicines.org.uk/emc/product/12028/smpc. Accessed 12 Jan 2023., EMC. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension - summary of product characteristics. 2022. https://www.medicines.org.uk/emc/product/12028/smpc. Accessed 12 Jan 2023.
Julian Higgins, Sally Green (2010)
Cochrane Handbook for Systematic Reviews of InterventionsInternational Coaching Psychology Review
G. Ferguson, P. Darken, S. Ballal, M. Siddiqui, Barinder Singh, S. Attri, U. Holmgren, E. Nigris (2020)
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysisAdvances in Therapy, 37
M. Borenstein, L. Hedges, J. Higgins, H. Rothstein (2010)
A basic introduction to fixed‐effect and random‐effects models for meta‐analysisResearch Synthesis Methods, 1
D. Lipson, H. Barnacle, R. Birk, N. Brealey, N. Locantore, D. Lomas, A. Ludwig-Sengpiel, R. Mohindra, M. Tabberer, Chang-Qing Zhu, S. Pascoe (2017)
FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 196
Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension -summary of product characteristics
S. Suissa, S. Dell'aniello, P. Ernst (2021)
Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety.Respiratory medicine, 189
G. Ferguson, N. Brown, C. Compton, T. Corbridge, K. Dorais, C. Fogarty, C. Harvey, M. Kaisermann, D. Lipson, Neil Martin, F. Sciurba, M. Stiegler, Chang-Qing Zhu, D. Bernstein (2020)
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trialsRespiratory Research, 21
D. Lipson, F. Barnhart, N. Brealey, Jean Brooks, G. Criner, Nicola Day, M. Dransfield, D. Halpin, M. Han, Elaine Jones, S. Kilbride, P. Lange, D. Lomas, F. Martinez, Dave Singh, M. Tabberer, R. Wise, S. Pascoe (2018)
Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPDThe New England Journal of Medicine, 378
P. Rogliani, J. Ora, F. Cavalli, M. Cazzola, L. Calzetta (2022)
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS ScoreJournal of Clinical Medicine, 11
G. Ferguson, K. Rabe, F. Martinez, L. Fabbri, Chen Wang, M. Ichinose, E. Bourne, S. Ballal, P. Darken, K. DeAngelis, M. Aurivillius, P. Dorinsky, C. Reisner (2018)
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.The Lancet. Respiratory medicine, 6 10
J. Deeks, J. Higgins, D. Altman (2019)
Analysing data and undertaking meta‐analysesCochrane Handbook for Systematic Reviews of Interventions
JJ Deeks (2008)
243
A. Laws, R. Kendall, N. Hawkins (2014)
A comparison of national guidelines for network meta-analysis.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17 5
Hyun Lee, Hyung-Jun Kim, E. Jang, Chang-Hoon Lee (2021)
Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-AnalysisRespiration, 100
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
G. Feldman, A. Sousa, D. Lipson, L. Tombs, N. Barnes, J. Riley, Sadhana Patel, I. Naya, C. Compton, B. Navarrete (2017)
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized StudyAdvances in Therapy, 34
Adv Ther https://doi.org/10.1007/s12325-023-02495-0 LETTER A Response to: Letter to the Editor Regarding ‘‘Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis’’ . . . . Afisi S. Ismaila Katrin Haeussler Mia Malmena¨s Raj Sharma . . . Chris Compton Claus F. Vogelmeier MeiLan K. Han David M. G. Halpin Received: January 31, 2023 / Accepted: March 9, 2023 The Author(s) 2023 Keywords: COPD; Fixed-effects model; (NMA) of fluticasone furoate/umeclidinium/ Fluticasone furoate/umeclidinium/vilanterol; vilanterol (FF/UMEC/VI) triple therapy com- Heterogeneity; Indirect treatment comparison; pared with other therapies for the treatment of Network meta-analysis; Random effects model; chronic obstructive pulmonary disease (COPD) Triple therapy [1]. To minimize clinical heterogeneity across COPD studies, we conducted two separate Dear Editor, NMAs [1, 2] and presented the data in parallel in the same journal. The dual therapy NMA [2] We would like to thank you for allowing us the included studies from patients who were mostly opportunity to respond to the letter received symptomatic with infrequent exacerbations to from Marshall et al. and to address the queries ensure that the long-acting b -agonist (LABA)/ raised with respect to our network meta-analysis long-acting muscarinic antagonist (LAMA) C. F. Vogelmeier
Advances in Therapy – Springer Journals
Published: Apr 1, 2023
Keywords: COPD; Fixed-effects model; Fluticasone furoate/umeclidinium/vilanterol; Heterogeneity; Indirect treatment comparison; Network meta-analysis; Random effects model; Triple therapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.